Format

Send to

Choose Destination
Tumour Biol. 2017 Jul;39(7):1010428317714626. doi: 10.1177/1010428317714626.

Progress in the treatment of advanced gastric cancer.

Author information

1
1 Department of General Surgery, China-Japan Union Hospital of Jilin University, Changchun, People's Republic of China.
2
2 Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun, People's Republic of China.

Abstract

Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.

KEYWORDS:

Advanced gastric cancer; immunotherapy; molecular-targeted therapies radiotherapy; neoadjuvant chemotherapy

PMID:
28671042
DOI:
10.1177/1010428317714626
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center